TREM-1 - Expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases

Journal of Clinical Investigation

Volumn 117, Issue 10, 2007, Pages 3097-3106

  Schenk, Mirjam ^a   Bouchon, Axel ^b   Seibold, Frank ^a   Mueller, Christoph ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN RECEPTOR; PEPTIDE; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; ENTERITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, IMMUNOLOGIC;

EID: 34948821265     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30602     Document Type: Article

References (36)

1. Bouchon, A., Cella, M., Grierson, H.L., Cohen, J.I., and Colonna, M. 2001. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J. Immunol. 167:5517-5521.
2. Bouchon, A., Facchetti, F., Weigand, M.A., and Colonna, M. 2001. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 410:1103-1107.
3. Schenk, M., Bouchon, A., Birrer, S., Colonna, M., and Mueller, C. 2005. Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine. J. Immunol. 174:517-524.
4. Bouchon, A., Dietrich, J., and Colonna, M. 2000. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J. Immunol. 164:4991-4995.
5. Gibot, S., et al. 2004. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J. Exp. Med. 200:1419-1426.
6. Gibot, S., et al. 2005. Surface and soluble triggering receptor expressed on myeloid cells-1: expression patterns in murine sepsis. Crit. Care Med. 33:1787-1793.
7. Gibot, S. 2005. Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis. Crit. Care. 9:485-489.
8. Hanauer, S.B., et al. 2002. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359:1541-1549.
9. Bouma, G., and Strober, W. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521.
10. Macdonald, T.T., and Monteleone, G. 2005. Immunity, inflammation, and allergy in the gut. Science. 307:1920-1925.
11. Smith, P.D., et al. 2001. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J. Immunol. 167:2651-2656.
12. Powrie, F., Leach, M.W., Mauze, S., Caddle, L.B., and Coffman, R.L. 1993. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5:1461-1471.
13. Morrissey, P.J., Charrier, K., Braddy, S., Liggitt, D., and Watson, J.D. 1993. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J. Exp. Med. 178:237-244.
14. Corazza, N., Eichenberger, S., Eugster, H.P., and Mueller, C. 1999. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J. Exp. Med. 190:1479-1492.
15. Dieleman, L.A., et al. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology. 107:1643-1652.
16. Kitajima, S., Takuma, S., and Morimoto, M. 1999. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp. Anim. 48:137-143.
17. Ni, J., Chen, S.F., and Hollander, D. 1996. Immunological abnormality in C3H/HeJ mice with heritable inflammatory bowel disease. Cell Immunol. 169:7-15.
18. Okayasu, I., et al. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 98:694-702.
19. Maeda, S., et al. 2005. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science. 307:734-738.
20. Gibot, S. 2006. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia and severe sepsis. Semin. Respir. Crit. Care Med. 27:29-33.
21. Gibot, S., et al. 2005. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med. 31:594-597.
22. Gibot, S., et al. 2004. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann. Intern. Med. 141:9-15.
23. Knapp, S., et al. 2004. Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J. Immunol. 173:7131-7134.
24. Bleharski, J.R., et al. 2003. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J. Immunol. 170:3812-3818.
25. Keane, J., et al. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345:1098-1104.
26. Tzivras, M., et al. 2006. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J. Gastroenterol. 12:3416-3419.
27. Hamerman, J.A., et al. 2006. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J. Immunol. 177:2051-2055.
28. Turnbull, I.R., et al. 2006. Cutting edge: TREM-2 attenuates macrophage activation. J. Immunol. 177:3520-3524.
29. Takeda, K., et al. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 10:39-49.
30. Kamada, N., et al. 2005. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J. Immunol. 175:6900-6908.
31. Rogler, G., et al. 1997. Alterations of the phenotype of colonic macrophages in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 9:893-899.
32. Smith, P.D., Ochsenbauer-Jambor, C., and Smythies, L.E. 2005. Intestinal macrophages: unique effector cells of the innate immune system. Immunol. Rev. 206:149-159.
33. Smythies, L.E., et al. 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115:66-75. doi:10.1172/JCI200519229.
34. Jung, S., et al. 2000. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 20:4106-4114.
35. Geissmann, F., Jung, S., and Littman, D.R. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity. 19:71-82.
36. Rogler, G., et al. 1998. Isolation and phenotypic characterization of colonic macrophages. Clin. Exp. Immunol. 112:205-215.